Diovan Generic Exclusivity Mystery Deepens After Judge Tosses Mylan Lawsuit

Court says FDA handled changed USP monograph appropriately, but ruling sheds no new light on the status of first-filer Ranbaxy’s tentatively approved valsartan ANDA or when the first generic version of Novartis’ single-ingredient anti-hypertensive agent will enter the market.